In This Article:
Company Announcement
COPENHAGEN, Denmark; July 4, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program.
The share buy-back program is expected to be completed no later than August 31, 2022 and comprises up to 370,000 shares.
The following transactions were executed under the program from June 27, 2022 to July 1, 2022:
|
| No. of shares | Average price (DKK) | Total value (DKK) |
| Accumulated through last announcement | 72,000 |
| 152,482,980 |
| June 27, 2022 | 13,000 | 2,265.64 | 29,453,320 |
| June 28, 2022 | 13,000 | 2,248.06 | 29,224,780 |
| June 29, 2022 | 13,000 | 2,226.95 | 28,950,350 |
| July 1, 2022 | 5,000 | 2,322.09 | 11,610,450 |
| Total | 57,000 |
| 128,986,930 |
| Accumulated under the program | 129,000 |
| 281,469,910 |
Details of each transaction are included as an appendix to this announcement.
Following these transactions, Genmab holds 362,885 shares as treasury shares, corresponding to 0.55% of the total share capital and voting rights.
The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 22 dated June 17, 2022.
About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com